Chromocell Therapeutics Corp

AMEX:CHRO (USA)  
$ 2.21 -0.32 (-12.65%) 03:10 PM EST
At Loss
Market Cap:
$ 12.99M
Enterprise V:
$ 16.04M
Volume:
20.94K
Avg Vol (2M):
24.49K
Volume:
20.94K
At Loss
Avg Vol (2M):
24.49K

Business Description

Chromocell Therapeutics Corp
NAICS : 541713 SIC : 8731
ISIN : US1711261057
Compare
Compare
Traded in other countries / regions
CHRO.USA
IPO Date
2024-02-16
Description
Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.
Name Current Vs Industry Vs History
Cash-To-Debt 0.08
Equity-to-Asset -67.14
Debt-to-Equity -0.2
Debt-to-EBITDA -0.19
Piotroski F-Score N/A/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 87.92
9-Day RSI 75
14-Day RSI 63.36

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.01
Quick Ratio 0.01
Cash Ratio 0.01

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio 14.7
Name Current Vs Industry Vs History
ROA % -12100
ROIC % -493.32

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -2.34
EV-to-EBITDA -2.34
EV-to-FCF -12.16
Earnings Yield (Greenblatt) % -42.74
FCF Yield % -7.55

Financials

CHRO's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with AMEX:CHRO

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Chromocell Therapeutics Corp Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -1.212
Beta 0
Volatility % 0
14-Day RSI 63.36
14-Day ATR ($) 0.281644
20-Day SMA ($) 1.713605
12-1 Month Momentum % 0
52-Week Range ($) 1.21 - 6
Shares Outstanding (Mil) 5.88

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Chromocell Therapeutics Corp Filings

Filing Date Document Date Form
No Filing Data

Chromocell Therapeutics Corp Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Chromocell Therapeutics Corp Frequently Asked Questions

What is Chromocell Therapeutics Corp(CHRO)'s stock price today?
The current price of CHRO is $2.21. The 52 week high of CHRO is $6.00 and 52 week low is $1.21.
When is next earnings date of Chromocell Therapeutics Corp(CHRO)?
The next earnings date of Chromocell Therapeutics Corp(CHRO) is .
Does Chromocell Therapeutics Corp(CHRO) pay dividends? If so, how much?
Chromocell Therapeutics Corp(CHRO) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1